Paritaprevir/Ombitasvir/Ritonavir

帕利普韦/奥比他韦/利托那韦

Report date: 2026/05/13 20:02:10

Base Information

Drug NameParitaprevir/Ombitasvir/Ritonavir
Drug Alias Name利托那韦/Ombitasvir/ParitaprevirRitonavir/Ombitasvir/Paritaprevir奥比帕利Paritaprevir/Ritonavir/OmbitasvirParitaprevir Ritonavir and Ombitasvir +[13] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitorsNonstructural protein 5A inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsDecompensated Liver CirrhosisFibrosisHypersensitivity +[8] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryEU
Original Approved Date2015/01/14
Country/TerritoryBelgiumBulgariaCanada +[33] 
CombinationsYes ParitaprevirOmbitasvirRitonavir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie AgAbbvie Inc
Inactive CompaniesFournier Laboratories Ireland LtdAbbvie Ireland Nl BvAbbvie Deutschland Gmbh & Co Kg +[4] 
Active IndicationsHepatitis C, ChronicHepatitis C
Inactive IndicationsDecompensated Liver CirrhosisFibrosisHypersensitivity +[6] 

Other Information

ATC CodeJ05AP53
Related LinksWikipediaKEGG